Evidence map›Paper›PMID 20103038›Full record

ArticleAmerican journal of ophthalmology2010

From the laboratory to the clinic: molecular genetic testing in pediatric ophthalmology.

Arlene V Drack, Scott R Lambert, Edwin M Stone

Open access · greenAbstract read
In one paragraph

Article in American journal of ophthalmology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Genetic Testing in Pediatric Ophthalmology.Indian journal of pediatrics · 2018
    Review
  5. Article
  6. Article
  7. Article
  8. Genetic diagnostic methods for inherited eye diseases.Middle East African journal of ophthalmology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Arlene V DrackDepartment of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. arlene-drack@uiowa.edu
Scott R Lambert
Edwin M Stone
University of Iowa · USEmory University · US

Funding

Molecular Genetics of Age Related Macular DegenerationR01EY016822 · NEI · UNIVERSITY OF IOWA · PI STONE, EDWIN M · 2005 to 2013
$4.0M
MOLECULAR GENETICS OF CORNEAL DYSTROPHIESR01EY011543 · NEI · UNIVERSITY OF IOWA · PI STONE, EDWIN M · 1996 to 2000
$316k
MOLECULAR GENETICS OF MACULAR DEGENERATIONR01EY010539 · NEI · UNIVERSITY OF IOWA · PI STONE, EDWIN M · 1994 to 1998
–
Howard Hughes Medical InstituteNEI NIH HHS R01 EY010539NEI NIH HHS R01 EY011543NEI NIH HHS R01 EY016822
6 · The paper itself

Abstract

purposeTo review the current state of molecular genetic testing as it relates to pediatric ophthalmology and to discuss its uses.

designReview and evaluation of available molecular genetic testing.

methodsLiterature review and discussion of testing in practice based on the authors' clinical and laboratory experience.

resultsFee-for-service testing for many genetic eye diseases now is available. A report is always generated for fee-for-service testing. Detection of DNA variants in genes known to cause eye disease must be interpreted taking into account the variability of the human genome, the presence of benign variants (polymorphisms), and the carrier frequency of recessive alleles. Negative results in genetic testing are helpful in some disorders for which most of the causative genes are known and many disease-causing variants have already been reported, but are less helpful in those that currently have many undiscovered causative genes or novel mutations. Research-based testing also is available, but does not always yield a result. Patients with RPE65-associated Leber congenital amaurosis may be eligible for the current gene therapy trial. Patients with a variety of disorders may benefit from improved surveillance if their genetic diagnosis is known.

conclusionsEntry into the genetic testing system often is via the patient's ophthalmologist. Collaboration with geneticists and genetic counselors, use of web sites to keep up with the ever-changing availability and detection rates, and knowledge of clinical trials, when combined with excellent clinical diagnosis, can improve diagnosis and allow eligible patients to participate in treatment trials.

Indexed as

Genetic Predisposition to DiseaseMolecular Diagnostic TechniquesChild, PreschoolEye Diseases, HereditaryGenetic TestingHumansInfantInfant, NewbornOphthalmology

Identifiers

PMID20103038
PMCPMC2813223
OpenAlexW1980499545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.